证券代码：301122 证券简称：采纳股份 公告编号：2025-075 采纳科技股份有限公司 关于使用部分闲置募集资金和自有资金 进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险 的前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含 超募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内， 资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披 ...

归创通桥(02190)发布公告，于2025年8月19日，董事会审议及批准有关建议采纳股份（301122）激励计 划的决议案。股份激励计划将以发行新H股(包括转让库存股)拨资，因而构成《上市规则》第十七章所 界定涉及公司发行新股份的股份计划。采纳股份激励计划须待股东批准后，方可作实。 ...

Core Viewpoint - The company, Zhichuang Tongqiao (02190), announced the approval of a proposed share incentive plan by its board of directors, which is set to be reviewed on August 19, 2025, and requires shareholder approval to be implemented [1] Group 1 - The share incentive plan will involve the issuance of new H-shares, including the transfer of treasury shares, thus constituting a share plan as defined under Chapter 17 of the Listing Rules [1] - The implementation of the share incentive plan is contingent upon receiving approval from the shareholders [1]

Group 1 - The stock price of CaiNa Co., Ltd. was 23.57 yuan as of August 14, 2025, down 0.97 yuan or 3.95% from the previous trading day's closing price [1] - The company operates in the medical device sector, focusing on the research, production, and sales of medical devices [1] - On August 14, 2025, a block trade occurred involving 1.6575 million shares at a transaction value of 33.9953 million yuan, with a transaction price of 20.51 yuan, representing a 12.98% discount to the closing price [1] Group 2 - The block trade accounted for 52.90% of the total transaction value on that day [1] - On August 14, 2025, the net outflow of main funds for CaiNa Co., Ltd. was 703,900 yuan, which is 0.04% of the circulating market value [1] - Over the past five days, the net outflow of main funds totaled 21.9651 million yuan, representing 1.38% of the circulating market value [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交全额 买方营业部 (万元) | | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-14 | 301122 | 采纳股份 | 20.51 | 165.75 | 3,399.53 万宏源证券有限 | | 机构专用 | | | | | | | | 公司上海金山区蒙 | | | | | | | | | 山路证券营业部 | | 8月14日，采纳股份大宗交易成交165.75万股，成交额3399.53万元，占当日总成交额的34.6%，成交价20.51元，较市场收盘 价23.57元折价12.98%。 ...

证券日报网讯采纳股份（301122）8月12日在互动平台回答投资者提问时表示，截至2025年8月8日，在 中国证券登记结算有限责任公司深圳分公司登记在册的公司股东数为8411户。 ...

Group 1 - The core viewpoint of the news is that Canan Technology Co., Ltd. has experienced a significant decline in its financial performance, with a notable drop in revenue and net profit in the latest quarterly report [1] - As of August 11, Canan's stock closed at 24.88 yuan, up 3.28%, with a rolling PE ratio of 85.13, marking a new low in 176 days [1] - The company's total market capitalization is 3.041 billion yuan, ranking 103rd in the medical device industry, which has an average PE ratio of 56.56 and a median of 39.76 [1][2] Group 2 - In terms of financial performance, Canan reported a revenue of 72.7093 million yuan for Q1 2025, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34% [1] - The gross profit margin for the company stands at 31.15% [1] - The company specializes in the research, production, and sales of injection and puncture instruments and laboratory consumables, and is recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1]

Core Points - The stock price of Canar Co., Ltd. (301122) closed at 24.09 yuan on August 8, 2025, with a 1.6% increase and a turnover rate of 6.02% [1] - The company reported a total revenue of 72.71 million yuan for Q1 2025, a year-on-year decrease of 34.28%, and a net profit attributable to shareholders of 7.68 million yuan, down 69.34% year-on-year [1] - Canar Co., Ltd. was established in 2004 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 1.22 billion yuan [2] Financial Performance - The latest financial report indicates a significant decline in performance, with a net profit decrease of 69.34% and a non-recurring net profit decrease of 78.81% [1] - The liquidity ratios are strong, with a current ratio of 9.215 and a quick ratio of 8.400, while the debt-to-asset ratio stands at 7.51% [1] Investment and Intellectual Property - Canar Co., Ltd. has made investments in 7 companies and participated in 20 bidding projects [2] - The company holds 49 trademark registrations and 93 patents, along with 56 administrative licenses [2]

Core Viewpoint - The announcement details a significant reduction in shareholding by a major shareholder, China Insurance, which has decreased its stake in the company from over 5% to just below 5%, indicating a potential shift in shareholder dynamics and control [1][2]. Group 1: Shareholder Changes - China Insurance held 7,146,348 shares, representing 5.8459% of the total share capital before the reduction [2]. - After the reduction, China Insurance now holds 6,112,253 shares, which is 4.99998% of the total share capital, thus no longer being classified as a major shareholder [1][2]. - The reduction involved selling 1,034,095 shares, accounting for 0.8459% of the total share capital, with an average selling price of 23.2741 yuan per share [2]. Group 2: Compliance and Regulations - The company has adhered to relevant regulations and guidelines regarding shareholder equity changes, including the self-regulatory guidelines for listed companies and the interim measures for shareholder reductions [2]. - The announcement confirms that the change in shareholding will not affect the company's governance structure or ongoing operations [2].

Core Viewpoint - The report details the equity change of Citic Prudential Life Insurance Co., Ltd. in Canar Technology Co., Ltd., indicating a reduction in shareholding below 5% [1][2]. Group 1: Equity Change Details - Citic Prudential Life Insurance reduced its shareholding from 7,146,348 shares (5.8459%) to 6,112,253 shares (4.99998%) [8]. - The reduction involved selling 1,034,095 shares, which represents a decrease of 0.8459% in the total shareholding [8]. - The shares were sold through centralized bidding from July 30, 2025, to August 6, 2025 [9]. Group 2: Future Plans - Citic Prudential Life Insurance plans to continue reducing its holdings, with a maximum of 3,667,300 shares (up to 3% of the total share capital) to be sold within three months following the announcement made on April 24, 2025 [6][7]. - There are no plans for increasing shareholding in the next 12 months [6]. Group 3: Compliance and Disclosure - The report confirms that all necessary authorizations and approvals for the equity change have been obtained, ensuring compliance with relevant laws and regulations [1][2]. - Citic Prudential Life Insurance has committed to the accuracy and completeness of the report, taking legal responsibility for any misrepresentation [2][10].